Does Medi-Cal Cover HRT for Menopause? Coverage, Access, and Rules

Yes, Medi-Cal does cover hormone replacement therapy for menopause. A range of FDA-approved estrogen and progestogen products sit on the Medi-Cal Rx Contract Drugs List, which means beneficiaries with a valid prescription can fill them at any pharmacy that accepts Medi-Cal. Non-hormonal medications for hot flashes and related symptoms are covered too.¹

Which Hormone Therapies Are Covered

The Contract Drugs List is the centralized formulary for outpatient prescription drug coverage across all Medi-Cal beneficiaries. On the estrogen side, it includes estradiol as tablets, transdermal patches, and vaginal cream or ring; conjugated estrogens as tablets, capsules, and vaginal cream; and esterified estrogens as tablets and capsules. For progestogens, it includes micronized progesterone capsules and norethindrone acetate combined with ethinyl estradiol.²

In February 2026, the formulary added a 0.45 mg strength of conjugated estrogens and two conjugated estrogen-medroxyprogesterone acetate combination products (0.3 mg–1.5 mg and 0.45 mg–1.5 mg).²

An analysis by the California Health Benefits Review Program found that 100% of Medi-Cal enrollees have baseline coverage for most oral, topical systemic, and transdermal hormone therapies with no utilization management attached. Laboratory tests used to evaluate menopause symptoms are also fully covered without utilization management.³

Non-Hormonal Options for Symptom Relief

If you cannot take hormones or would rather not, Medi-Cal covers several alternatives on the Contract Drugs List:

SNRIs: venlafaxine and desvenlafaxine
SSRIs: citalopram, paroxetine, and escitalopram
Fezolinetant, an NK3 receptor antagonist approved specifically for hot flashes
Gabapentin in tablets, capsules, and oral solution
Oxybutynin in patches, tablets, and syrup, which can help with hot flashes as well as urinary symptoms

Medi-Cal’s Drug Use Review guidance also recognizes non-drug approaches for vasomotor symptoms, including cognitive behavioral therapy, clinical hypnosis, weight loss, and stellate ganglion blockade.¹

How To Get HRT Through Medi-Cal

Start with a healthcare provider who has prescribing authority. That can be a primary care physician, OB/GYN, endocrinologist, nurse practitioner, or physician assistant. The provider will review your medical history, screen for anything that would rule out hormone therapy, and discuss options with you before writing a prescription.¹

Since January 2022, all outpatient prescription drugs for Medi-Cal members have been handled through Medi-Cal Rx on a fee-for-service basis, whether or not you are enrolled in a managed care plan.⁴ Once you have the prescription, fill it at any pharmacy that takes Medi-Cal. To confirm a specific medication is currently on the formulary, check the Contract Drugs and Covered Products Lists page on the Medi-Cal Rx portal.

Clinical Rules That Affect Your Prescription

Providers are expected to prescribe the lowest effective dose and to weigh the route of administration. Patches and vaginal preparations may be preferred over pills for some patients because of their risk profile.

One rule matters for almost everyone considering estrogen. If you still have your uterus and take systemic estrogen, you must also take a progestogen to protect against endometrial cancer. If you have had a hysterectomy, estrogen alone is appropriate.¹

Timing matters too. Hormone therapy is considered most beneficial when started before age 60 or within 10 years of menopause onset. Starting therapy later than that, or continuing it past age 65, calls for a formal shared decision-making conversation about risks and benefits.

Contraindications that generally rule out hormone therapy include unexplained vaginal bleeding, liver disease, a history of estrogen-sensitive cancer (including breast cancer), coronary heart disease, prior stroke or heart attack, venous thromboembolism, and severely uncontrolled blood pressure above 180/110.¹

What Faces Extra Restrictions

Not every menopause-related drug is available without hurdles. According to the CHBRP analysis, topical testosterone, high-dose vaginal estrogen, fezolinetant, ospemifene, and prasterone all had some form of utilization management at baseline across California health plans, including Medi-Cal managed care. Osteoporosis medications carry utilization management across the board.⁵ If your provider wants to prescribe something that is not on the Contract Drugs List, coverage may still be possible but will require authorization from a Medi-Cal consultant.

Compounded Bioidentical Hormones

Compounded bioidentical hormone products are generally not recommended under Medi-Cal. The program’s guidance points to inconsistent dosing, potential impurities, sterility concerns, limited scientific data, and minimal government oversight. They are considered appropriate only in narrow situations, such as a documented allergy to an ingredient in an FDA-approved product or a dosage that is not available in any approved formulation.¹

Coverage Changes That May Be Coming

California is working on expanding menopause coverage, though the picture is unsettled. In October 2025, Governor Newsom vetoed Assembly Bill 432, which would have required health plans to cover menopause evaluation and treatment without utilization management. A spokesperson for the governor said the bill “would have unintentionally raised health care costs for millions of working women and working families already stretched thin.”⁶

In February 2026, the governor proposed a budget trailer bill that would add a new section to the Welfare and Institutions Code (Section 14132.14) making FDA-approved menopause treatments a covered Medi-Cal benefit, subject to medical necessity. It would also direct the Department of Health Care Services to establish reimbursement policies for menopause-related services and to consider clinical guidelines from the Menopause Society.⁷

The trailer bill also exempts Medi-Cal managed care plans from several of the broader reforms it applies to commercial insurers, including new screening requirements and utilization review changes.⁷ Assemblymember Rebecca Bauer-Kahan called that exclusion a “gaping hole” and a “significant equity issue,” noting that the program serves 7.6 million women and girls who are disproportionately Black and Latina, and indicated that closing the gap is a future legislative priority.⁸

A separate measure, SB 418, would require health plans and Medi-Cal to cover up to a 12-month supply of FDA-approved prescription hormone therapy and would prohibit utilization controls that limit the supply to less than 12 months. That bill explicitly applies to Medi-Cal.⁴ As of mid-2026, both the trailer bill and SB 418 are still under legislative consideration.

1
Medi-Cal Rx (DHCS). Drug Use Review: Menopausal Hormone Therapy for Bothersome Vasomotor Symptoms
2
Medi-Cal Rx (DHCS). Medi-Cal Rx Contract Drugs List
3
California Health Benefits Review Program. Analysis of Assembly Bill 432: Menopause
4
California Health Benefits Review Program. Analysis of SB 418: Prescription Hormone Therapy and Nondiscrimination
5
California Health Benefits Review Program. Key Findings: Analysis of Assembly Bill 432
6
ABC News. Halle Berry Criticizes Governor Newsom Over Menopause Bill Veto
7
California Department of Finance. Trailer Bill 1385: Menopause Health Care Coverage
8
Capital and Main. From Invisibility to Inclusion: A Generational Shift on Menopause Care